Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Medical guidelines and safety protocols strongly advise against taking semaglutide one week and tirzepatide the next, primarily due to the increased risk of compounded side effects and the lack of research on such combinations
What risks and side effects are possible
Understanding these aspects helps manage them effectively and ensures a safer treatment journey
The Medicines and Healthcare products Regulatory Agency (MHRA) approved this once-weekly subcutaneous injection to improve glycaemic control when diet and exercise alone are insufficient, either as monotherapy (when metformin is inappropriate) or in combination with other glucose-lowering medications
